LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Kodu・Aktsiate loetelu・ADMA Biologics Inc

ADMA Biologics Inc

Suletud

Sektor Tervishoid

15.66 0.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.33

Max

15.78

Põhinäitajad
By Trading Economics
Sissetulek	35M 18M
Müük	8M 82M
Aktsiakasum	0.08
Kasumimarginaal	21.748
Töötajad	624
EBITDA	7.9M 24M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+21.64 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2024

Turustatistika
By TradingEconomics
Turukapital	-671M 3.8B
Eelmine avamishind	15.21
Eelmine sulgemishind	15.66

Uudiste sentiment

By Acuity

77%

23%

367 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 16.44 Toetus ja vastupanu

ADMA Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. okt 2024, 21:55 UTC

Suurimad hinnamuutused turgudel

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders -- Update

22. okt 2024, 21:48 UTC

Peamised uudised

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders -- Update

22. okt 2024, 21:37 UTC

Suurimad hinnamuutused turgudel

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

22. okt 2024, 21:30 UTC

Suurimad hinnamuutused turgudel

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders

22. okt 2024, 21:12 UTC

Peamised uudised

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders

22. okt 2024, 20:52 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance After Sales Slump Persists

22. okt 2024, 20:49 UTC

Peamised uudised

Tulu

Canadian National Railway Posts Higher Revenue, Lower Profit in 3Q

22. okt 2024, 20:28 UTC

Tulu

Texas Instruments Posts Lower 3Q Revenue

22. okt 2024, 23:24 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance as Sales Slump Persists -- 2nd Update

22. okt 2024, 22:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. okt 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

22. okt 2024, 22:46 UTC

Peamised uudised

Meta Bans Accounts That Track Celebrity Jet Travel, Including for Zuckerberg -- WSJ

22. okt 2024, 22:45 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 3rd Update

22. okt 2024, 21:58 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance as Sales Slump Persists -- Update

22. okt 2024, 21:53 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 2nd Update

22. okt 2024, 21:19 UTC

Peamised uudised

Texas Instruments' Guidance Falls Short. The Stock Is Rising Anyway. -- Barrons.com

22. okt 2024, 21:14 UTC

Tulu

3M Produces Beat-and-Raise Earnings. The Stock Dropped. -- Barrons.com

22. okt 2024, 21:05 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- Update

22. okt 2024, 20:55 UTC

Tulu

Philip Morris International Stock Surges to Record -- WSJ

22. okt 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

22. okt 2024, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. okt 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. okt 2024, 20:48 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- WSJ

22. okt 2024, 20:45 UTC

Peamised uudised

Treasury Yields Rise, S&P 500 Edges Lower After Earnings Flurry -- WSJ

22. okt 2024, 20:45 UTC

Tulu

GE Aerospace Stock Skids Amid Commercial-Engine Concerns -- WSJ

22. okt 2024, 20:34 UTC

Peamised uudised

Tulu

Starbucks Stock Drops After Company Misses Earnings, Suspends Guidance -- Barrons.com

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q U.S. Drilling Lower 48 Avg Rig Count of Approximately 68 Rigs >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects Full-Yr Cap Expenditures of Approximately $600M, With $230M for the SANAD Newbuilds >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q International Avg Rig Count of Approximately 84 Rigs >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q Cap Expenditures of $230M, With $105M for the Newbuilds in Saudi Arabia >NBR

Võrdlus sarnastega

Hinnamuutus

ADMA Biologics Inc Prognoos

Hinnasiht

By TipRanks

21.64% tõus

12 kuu keskmine prognoos

Keskmine 19 USD 21.64%

Kõrge 20 USD

Madal 18 USD

Põhineb 3 Wall Streeti analüütiku instrumendi ADMA Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi ADMA Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Sentiment

By Acuity

367 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.